Tenofovir and abacavir combination therapy: Lessons learned from an urban clinic population

AIDS Patient Care and STDs

Volumn 21, Issue 4, 2007, Pages 240-246

  Gilliam, Bruce L ^a   Sajadi, Mohammad M ^a   Amoroso, Anthony ^a   Davis, Charles E ^a   Cleghorn, Farley R ^b   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Palladium Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; DIDANOSINE; NEVIRAPINE; STAVUDINE; TENOFOVIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; URBAN POPULATION; VIRUS INHIBITION; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADULT; AGED; ANTI-HIV AGENTS; BALTIMORE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTICENTER STUDIES; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URBAN POPULATION; VIRAL LOAD;

EID: 34247625006     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0070     Document Type: Article

References (17)

1. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naïve HIV-infected patients. AIDS Patient Care STDs 2005;19:135-140.
2. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral- naïve subjects. J Infect Dis 2005;192:1921-1930.
3. Landman R, Descamps D, Peytavin G, et al. Early Virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS Study. HIV Clin Trials 2005;6:291-301.
4. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. [51]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2004.
5. Ruane PJ, Luber AD. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens. MedGenMed 2004;6:31.
6. Kuritzkes DR. Less than the sum of its parts: Failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. J Infect Dis 2005;192:1867-1868.
7. Hawkins T, Veikley W, St. Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005;39:406-411.
8. Lanier ER, Hazen R, Ross L, Freeman A, Harvey R. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J Acquir Immune Defic Syndr 2005;39:519-522.
9. Elion R, Cohen C, DeJesus E, et al. COL40263: Resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral naïve subjects. [53]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2004.
10. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-5693.
11. Parikh U, Koontz D, Sluis-Cremer N, et al. K65R: A multinulceoside resistance mutation of increasing prevalence exhibits bi-directional antagonism with TAM. [54]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2004.
12. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005;49:1139-1144
13. Hoogewerf M, Regez RM, Schouten WE, et al. Change to abacavir-lamivudine- tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003;362:1979-1980.
14. Ross LL, Gerondelis P, Rouse EG, et al. Impact of HIV resistance mutations, drug resistance and viral fitness on antiviral activity of tenofovir/abacavir/lamivudine in the ESS30009 study [Abstract 159]. In: Abstracts of the 13th International HIV Drug Resistance Workshop (Canary Islands). Antivir Ther 2004 9:S175.
15. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003;139(5 Pt 1):313-320.
16. Maitland D, Moyle G, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005;19:1183-1188.
17. Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naïve HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005;19:213-215.